Livskvalitet og søvnkvalitet etter 12 måneders behandling med CPAP eller apnéskinne hos pasienter med mild til moderat obstruktiv søvnapné (OSA).

Forskere fra Universitetet i Tromsø, Universitetssykehuset i Nord-Norge, Tannhelsetjenestens kompetansesenter Midt-Norge, NTNU, Arendal sykehus, Universitetet i Bergen og St. Olavs Hospital har i denne randomiserte kontrollerte studien undersøkt livskvalitet og søvnkvalitet hos 104 pasienter med mild til moderat obstruktiv søvnapné, behandlet med CPAP (55 pasienter) eller apnéskinne (49 pasienter). SF36-spørreskjema ble brukt for å evaluere livskvalitet og Pittsburgh Sleep Quality Index (PSQI) for å evaluere søvnkvaliteten. Etter 12 måneders behandling var søvnkvaliteten forbedret i begge gruppene, og forskerne konkluderte med at bedring i livskvalitet var svakt korrelert med rapportert søvnkvalitet ved både CPAP og apnéskinnebehandling.

Publisert 30.10.2020 / Sist oppdatert 28.10.2022

Lars M Berg, Torun K S Ankjell, Yi-Qian Sun, Tordis A Trovik, Oddveig G. Rikardsen, Anders Sjögren, Ketil Moen, Sølve Hellem, Vegard Bugten

Studien er publisert i International Journal of Otolaryngology

In this randomized controlled trial, patients with nonsevere obstructive sleep apnea (OSA) were treated with continuous positive airway pressure (CPAP) or a twin block mandibular advancement splint (MAS). The primary objective was to compare how CPAP and MAS treatments change the health-related quality of life (HRQoL) and self-reported sleep quality of patients after 12 months of treatment. In total, 104 patients were recruited: 55 were allocated to the CPAP treatment group and 49 to the MAS treatment group. We used the SF36 questionnaire to evaluate HRQoL and the Pittsburgh Sleep Quality Index (PSQI) to evaluate sleep quality. All patients were included in the intention-to-treat analyses. These analyses showed improvements in the SF36 physical component score (from 48.8 ± 7.6 at baseline to 50.5 ± 8.0 at follow-up, p=0.03) in the CPAP treatment group and in the mental component score (from 44.9 ± 12.1 to 49.3 ± 9.2, p=0.009) in the MAS treatment group. The PSQI global score improved in both the CPAP (from 7.7 ± 3.5 to 6.6 ± 2.9, p=0.006) and the MAS (8.0 ± 3.1 to 6.1 ± 2.6, p < 0.001) treatment groups. No difference was found between the treatment groups in any of the SF36 scores or PSQI global score at the final follow-up (p > 0.05) in any analysis. The improvement in the SF36 vitality domain moderately correlated to the improvement in the PSQI global score in both groups (CPAP: |r|=0.47, p < 0.001; MAS: |r|=0.36, p=0.01). In the MAS treatment group, we also found a weak correlation between improvements in the SF36 mental component score and PSQI global score (|r|=0.28, p=0.05). In conclusion, CPAP and MAS treatments lead to similar improvements in the HRQoL and self-reported sleep quality in nonsevere OSA. Improvements in aspects of HRQoL seem to be moderately correlated to the self-reported sleep quality in both CPAP and MAS treatments.